Resultados de procura - Alberto D’Angelo

  • Mostrando 1 - 11 Resultados de 11
Limitar resultados
  1. 1
    Recent Anti-KRASG12D Therapies: A “Possible Impossibility” for Pancreatic Ductal Adenocarcinoma

    Recent Anti-KRASG12D Therapies: A “Possible Impossibility” for Pancreatic Ductal Adenocarcinoma por Navid Sobhani, Matteo Pittacolo, Alberto D’Angelo, Giovanni Marchegiani

    Publicado 2025
    Ligazón do recurso
    Revisão
    Engadir a favoritos
    Gardado en:
  2. 2
    Updates on the CDK4/6 Inhibitory Strategy and Combinations in Breast Cancer

    Updates on the CDK4/6 Inhibitory Strategy and Combinations in Breast Cancer por Navid Sobhani, Alberto D’Angelo, Matteo Pittacolo, Giandomenico Roviello, Tobias Otto

    Publicado 2019
    Ligazón do recurso
    Pré-impressão
    Engadir a favoritos
    Gardado en:
  3. 3
    MSI and EBV Positive Gastric Cancer’s Subgroups and Their Link with Novel Immunotherapy

    MSI and EBV Positive Gastric Cancer’s Subgroups and Their Link with Novel Immunotherapy por Maria Grazia Rodriquenz, Giandomenico Roviello, Alberto D’Angelo, Daniele Lavacchi, Franco Roviello, Karol Połom

    Publicado 2020
    Ligazón do recurso Ligazón do recurso
    Revisão
    Engadir a favoritos
    Gardado en:
  4. 4
    Advances in anti-BRAF therapies for lung cancer

    Advances in anti-BRAF therapies for lung cancer por Giandomenico Roviello, Alberto D’Angelo, Marianna Sirico, Matteo Pittacolo, Felipe Umpierre Conter, Navid Sobhani

    Publicado 2021
    Ligazón do recurso Ligazón do recurso
    Revisão
    Engadir a favoritos
    Gardado en:
  5. 5
    Current State and Future Challenges for PI3K Inhibitors in Cancer Therapy

    Current State and Future Challenges for PI3K Inhibitors in Cancer Therapy por Marianna Sirico, Alberto D’Angelo, Caterina Gianni, Chiara Casadei, Filippo Merloni, Ugo De Giorgi

    Publicado 2023
    Ligazón do recurso Ligazón do recurso
    Revisão
    Engadir a favoritos
    Gardado en:
  6. 6
    Encorafenib, Binimetinib, and Cetuximab in BRAF V600E-Mutated Colorectal Cancer

    Encorafenib, Binimetinib, and Cetuximab in BRAF V600E-Mutated Colorectal Cancer por Giandomenico Roviello, Alberto D’Angelo, Roberto Petrioli, Franco Roviello, Fabio Cianchi, Stefania Nobili, Enrico Mini, Daniele Lavacchi

    Publicado 2020
    Ligazón do recurso
    Revisão
    Engadir a favoritos
    Gardado en:
  7. 7
    AR-V7 in Metastatic Prostate Cancer: A Strategy beyond Redemption

    AR-V7 in Metastatic Prostate Cancer: A Strategy beyond Redemption por Navid Sobhani, Praveen Neeli, Alberto D’Angelo, Matteo Pittacolo, Marianna Sirico, Ilaria Camilla Galli, Giandomenico Roviello, Gabriella Nesi

    Publicado 2021
    Ligazón do recurso Ligazón do recurso
    Revisão
    Engadir a favoritos
    Gardado en:
  8. 8
    Current Status of Fibroblast Growth Factor Receptor-Targeted Therapies in Breast Cancer

    Current Status of Fibroblast Growth Factor Receptor-Targeted Therapies in Breast Cancer por Navid Sobhani, Anna Ianza, Alberto D’Angelo, Giandomenico Roviello, Fabiola Giudici, Marina Bortul, Fabrizio Zanconati, Cristina Bottin, Daniele Generali

    Publicado 2018
    Ligazón do recurso Ligazón do recurso
    Revisão
    Engadir a favoritos
    Gardado en:
  9. 9
    Updates on the CDK4/6 Inhibitory Strategy and Combinations in Breast Cancer

    Updates on the CDK4/6 Inhibitory Strategy and Combinations in Breast Cancer por Navid Sobhani, Alberto D’Angelo, Matteo Pittacolo, Giandomenico Roviello, Anna Miccoli, Silvia Paola Corona, Ottavia Bernocchi, Daniele Generali, Tobias Otto

    Publicado 2019
    Ligazón do recurso Ligazón do recurso
    Revisão
    Engadir a favoritos
    Gardado en:
  10. 10
    Methylene Blue—Current Knowledge, Fluorescent Properties, and Its Future Use

    Methylene Blue—Current Knowledge, Fluorescent Properties, and Its Future Use por Tomasz Cwalinski, Wojciech Połom, Luigi Marano, Giandomenico Roviello, Alberto D’Angelo, Natalia Cwalina, Marcin Matuszewski, Giandomenico Roviello, Janusz Jaśkiewicz, Karol Połom

    Publicado 2020
    Ligazón do recurso Ligazón do recurso
    Revisão
    Engadir a favoritos
    Gardado en:
  11. 11
    Focus on ROS1-Positive Non-Small Cell Lung Cancer (NSCLC): Crizotinib, Resistance Mechanisms and the Newer Generation of Targeted Therapies

    Focus on ROS1-Positive Non-Small Cell Lung Cancer (NSCLC): Crizotinib, Resistance Mechanisms and the Newer Generation of Targeted Therapies por Alberto D’Angelo, Navid Sobhani, Robert Chapman, Stefan Bagby, Carlotta Bortoletti, Mirko Traversini, Katia Ferrari, Luca Voltolini, Jacob Darlow, Giandomenico Roviello

    Publicado 2020
    Ligazón do recurso Ligazón do recurso
    Revisão
    Engadir a favoritos
    Gardado en:

Ferramentas de procura: